As a new filing with the Securities and Exchange Commission showed, billionaire Steve Cohen‘s Point72 Asset Management has initiated a stake in Celator Pharmaceuticals Inc (NASDAQ:CPXX) amid a 500% jump registered by the stock. The 13G filing showed that Point72 currently owns almost 2.26 million shares of Celator, which represent 6.5% of the company’s outstanding stock.
Celator’s stock surged after the company announced positive results from the Phase 3 trial of its drug candidate in patients with blood cancer. Overall, the median survival for patients treated with Celator’s VYXEOS was 9.56 months, versus 5.96 months for patients treated with standard care regimen, known as 7+3. Celator plans to submit submit its New Drug Application later this year.
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Point7 | 0 | 2,255,000 | 0 | 2,255,000 | 2,255,000 | 6.5% |
Point7 | 0 | 2,255,000 | 0 | 2,255,000 | 2,255,000 | 6.5% |
EverPoint Asset Management | 0 | 600,000 | 0 | 600,000 | 600,000 | 1.7% |
Steven A. Cohen | 0 | 2,855,000 | 0 | 2,855,000 | 2,855,000 | 8.3% |
Follow Steven A. Cohen's Point72 Asset Management
Page 1 of 9 SEC Filing
(Amendment No. )*
CELATOR PHARMACEUTICALS, INC.
Common Stock, Par Value $0.001 Per Share
☐ | Rule 13d-1(b) | |
☒ | Rule 13d-1(c) | |
☐ | Rule 13d-1(d) |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 2 of 9 SEC Filing
CUSIP No. 15089R102 | 13G | Page 2 of 9 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Point72 Asset Management, L.P. | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 2,255,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 2,255,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,255,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.5% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* PN |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 3 of 9 SEC Filing
CUSIP No. 15089R102 | 13G | Page 3 of 9 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Point72 Capital Advisors, Inc. | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 2,255,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 2,255,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,255,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.5% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* CO |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 4 of 9 SEC Filing
CUSIP No. 15089R102 | 13G | Page 4 of 9 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON EverPoint Asset Management, LLC | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 600,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 600,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 600,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.7% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* OO |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 5 of 9 SEC Filing
CUSIP No. 15089R102 | 13G | Page 5 of 9 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Steven A. Cohen | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 2,855,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 2,855,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,855,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.3% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* IN |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 6 of 9 SEC Filing
Item 1(a) | Name of Issuer: |
Celator Pharmaceuticals, Inc. | |
Item 1(b) | Address of Issuer’s Principal Executive Offices: |
200 PrincetonSouth Corporate Center, Suite 180, Ewing, New Jersey 08628 | |
Item 2(a) | Name of Person Filing: |
This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of Common Stock, $0.001 par value per share (“Shares”), of the Issuer held by certain investment funds it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by certain investment funds managed by Point72 Asset Management; (iii) EverPoint Asset Management, LLC (“EverPoint Asset Management”) with respect to Shares held by certain investment funds it manages; and (iv) Steven A. Cohen with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and EverPoint Asset Management. | |
Point72 Asset Management, Point72 Capital Advisors Inc., EverPoint Asset Management and Steven A. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act. | |
Item 2(b) | Address or Principal Business Office: |
The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) EverPoint Asset Management is 510 Madison Avenue, New York, NY 10022. | |
Item 2(c) | Citizenship: |
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. EverPoint Asset Management is a Delaware limited liability company. Mr. Cohen is a United States citizen. | |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 7 of 9 SEC Filing
Item 2(d) | Title of Class of Securities: |
Common Stock, par value $0.001 per share | |
Item 2(e) | CUSIP Number: |
15089R102 | |
Item 3 | Not Applicable |
Item 4 | Ownership: |
The percentages used herein are calculated based upon the Shares of common stock issued and outstanding as of November 11, 2015, as reported on the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer for the quarterly period ended September 30, 2015. | |
As of the close of business on March 14, 2016: | |
1. Point72 Asset Management, L.P. | |
(a) Amount beneficially owned: 2,255,000 | |
(b) Percent of class: 6.5% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 2,255,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 2,255,000 | |
2. Point72 Capital Advisors, Inc. | |
(a) Amount beneficially owned: 2,255,000 | |
(b) Percent of class: 6.5% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 2,255,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 2,255,000 | |
3. EverPoint Asset Management, LLC | |
(a) Amount beneficially owned: 600,000 | |
(b) Percent of class: 1.7% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote:600,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 600,000 | |
4. Steven A. Cohen | |
(a) Amount beneficially owned: 2,855,000 | |
(b) Percent of class: 8.3% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 2,855,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 2,855,000 | |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 8 of 9 SEC Filing
Point72 Asset Management, Point72 Capital Advisors Inc., EverPoint Asset Management and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by certain investment funds it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, EverPoint Asset Management maintains investment and voting power with respect to the securities held by certain investment funds it manages. Mr. Cohen controls each of Point72 Capital Advisors Inc., and EverPoint Asset Management. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i) Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen may be deemed to beneficially own 2,255,000 Shares (constituting approximately 6.5% of the Shares outstanding); and (ii) EverPoint Asset Management and Mr. Cohen may be deemed to beneficially own 600,000 Shares (constituting approximately 1.7% of the Shares outstanding). Each of Point72 Asset Management, Point72 Capital Advisors Inc., EverPoint Asset Management and Mr. Cohen disclaims beneficial ownership of any of the securities covered by this statement. | |
Item 5 | Ownership of Five Percent or Less of a Class: |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐ | |
Item 6 | Ownership of More than Five Percent on Behalf of Another Person: |
Not Applicable | |
Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: |
Not Applicable | |
Item 8 | Identification and Classification of Members of the Group: |
Not Applicable | |
Item 9 | Notice of Dissolution of Group: |
Not Applicable | |
Item 10 | Certification: |
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)
Page 9 of 9 SEC Filing
EVERPOINT ASSET MANAGEMENT, LLC
STEVEN A. COHEN